

April 1, 2013

PRESS RELEASE

Mitsubishi Tanabe Pharma Corporation

## Transfer of Tanabe Europe's shares

**Osaka, Japan, April 1, 2013**---Mitsubishi Tanabe Pharma Corporation (President and Representative Director, CEO: Michihiro Tsuchiya) announced today that the Company entered into an agreement to transfer all shares of Tanabe Europe N.V., the Company's consolidated subsidiary, to API Corporation (Headquarters: Tokyo; President Representative Director: Kiyoshi Kondo).

### 1. Grounds for a transfer

Mitsubishi Tanabe Pharma, guided by the "Medium-Term Management Plan 11-15—New Value Creation," aims to focus management resources on our pharmaceutical operations by reorganizing operations. In this setting, the Company transferred its fine chemical operations in July, 2012. Subsequently, the Company decided to transfer the shares of Tanabe Europe, who is engaging in sales of chemicals and related products, in order to further focus management resources.

API Corporation, which is scheduled to acquire Tanabe Europe's shares, is a consolidated subsidiary of Mitsubishi Chemical Corporation, one of the operating companies of the Mitsubishi Chemical Holdings Group. API is aggressively developing its business, centered on its healthcare and fine chemical operations, in accordance with its corporate philosophy: "API Corporation aims at developing into a 'creative, R&D-oriented company' in the field of specialty fine chemicals and contributing to a higher quality of life for people throughout the world." The Company anticipates that the addition of Tanabe Europe's sales operations of chemicals and related products will enable API Corporation to achieve impressive levels of growth in the future.

Mitsubishi Tanabe Pharma, through this transfer of shares, we aim to further focus management resources on our pharmaceutical operations and to develop into a "Company that Can Continue to Create New Value."

### 2. Overview of Tanabe Europe N.V.

Location: Excelsiorlaan 83, 1930 Zaventem, Belgium

Representative: President and Director, Hiroshi Sato

Capital: €260,330

Net sales: €15,667,000 (estimation for fiscal year ended March 2013)

Operations: Sales of chemicals and related products

Number of employee: 6 (As of April 1, 2012)

3. Overview of API Corporation

Location: Nihonbashi Plaza Building, 9th Floor, 2-3-4, Nihonbashi, Chuo-ku, Tokyo, Japan

Representative: President and Representative Director, Kiyoshi Kondo

Capital: ¥4,000 million

Net sales: ¥27,327 million (fiscal year ended March, 2012)

Operations: Consigned manufacture of active pharmaceutical ingredients, intermediates and investigational new drugs, consigned research and development, manufacture and marketing of fine chemicals and reagents

Number of employee: 605 (As of April 1, 2012)

Major Shareholders: Mitsubishi Chemical Corporation (52.3%),  
Mitsubishi Tanabe Pharma Corporation (47.7%)

4. Schedule of transfer of shares

Date of the contract: March 29, 2013

Date of transfer: June 1, 2013 (planned)

5. Impact of financial results

It is thought that the impact on Mitsubishi Tanabe Pharma's financial results will be minor.

**<Media enquiry>**

Corporate Communications Department

TEL : +81-6-6205-5211